Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia.
Pau MontesinosChristian RecherSusana VivesEwa ZarzyckaJianxiang WangGiambattista BertaniMichael HeuserRodrigo do Tocantins CaladoAndre C SchuhSu-Peng YehScott R DaigleJianan HuiShuchi S PandyaDiego A GianolioStephane de BottonHartmut DöhnerPublished in: The New England journal of medicine (2022)
Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat population. Febrile neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group, whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group. (Funded by Agios Pharmaceuticals and Servier Pharmaceuticals; AGILE ClinicalTrials.gov number, NCT03173248.).